Companies Dominating the Noradrenergic Drug Landscape
- Baxter International, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Novartis AG
- Bayer AG
- Sanofi-aventis Groupe
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Pfizer Inc.
Browse Key Market Insights with Data Illustration:
In the News
-
Baxter International, Inc. introduced premix Norepinephrine Bitartrate in 5% Dextrose Injection, which can be can be kept in automated dispensing cabinets at the point-of-care and has a shelf life of up to 21 months in the refrigerator or up to 90 days at room temperature in overwrap. Further, it is used to treat individuals with acute or emergent hypotension
-
Sanofi-aventis Groupe acquired Provention Bio, Inc., to add TZIELD, the first disease-modifying therapy for the postponement of Stage 3 type 1 diabetes, to the portfolio. Further, the drug TZIELD (teplizumab-mzwv) can be used to postpone the onset of Stage 3 type 1 diabetes (T1D) in adults and children with Stage 2 T1D who are at least 8 years old.